ABT-494 pipeline developments
AbbVie (ABBV) expects investigational therapy ABT-494, a selective Janus Kinase 1 (or JAK1) inhibitor, to become a standard of care in the immunology space, similar to Humira. The drug is currently being studied in Phase 3 trials as a treatment option for rheumatoid arthritis (or RA). AbbVie expects to release data from these trials in 2018.
ABT-494 is also being studied as a therapy for gastrointestinal disorders such as Crohn’s disease and ulcerative colitis. AbbVie anticipates data from Phase 2 trials evaluating ABT-494 as a therapy for Crohn’s disease by the first half of 2017.
The company has also begun Phase 2 trials to evaluate oral ABT-494 as a treatment option for atopic dermatitis. To know more about ABT-494, please refer to AbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494.
If ABT-494 gets regulatory approvals for all the targeted indications, it may have a positive impact on AbbVie’s share prices as well as those of the iShares Core S&P 500 (IVV). AbbVie makes up about 0.51% of IVV’s total portfolio holdings.
Phase 3 program
The above chart shows six pivotal studies in the Phase 3 program that’s evaluating ABT-494 as an RA therapy. The company is also testing the investigational therapy for difficult-to-treat patients who have failed to respond to a first biologic therapy.
Additional multiple durations of therapy are also being researched. The company aims to uncover patient segments that can benefit from early intervention with ABT-494. These trials have been thus designed in a manner that can help ABT-494 secure regulatory approval for a broad label.
In the next part of this series, we’ll analyze the long-term growth potential of investigational oncology drug Venclexta.